Sophia Genetics SA (NASDAQ: SOPH) — Perfil da empresa, notícias e dados financeiros
Sophia Genetics specializes in data-driven medicine, utilizing AI for clinical and genomic data to improve patient outcomes.
Sophia Genetics SA
Sophia Genetics (NASDAQ:SOPH) specializes in data-driven medicine, focusing on the development and use of advanced computational techniques to support healthcare professionals in diagnosing and treating diseases. It operates globally, leveraging artificial intelligence to analyze clinical and genomic data with the aim to improve disease detection, treatment, and overall patient outcomes. Their projects range from cancer research to rare diseases, striving to break new ground in personalized medicine and collaborative healthcare networks. With a mission to make clinical genomics more accessible and actionable, Sophia Genetics is committed to transforming healthcare through data intelligence and contributing to a more sustainable global health ecosystem.
Resumo
Operações
Produtos e/ou serviços de Sophia Genetics SA
- Sophia DDM platform utilizes AI for genomic analysis, offering insights into complex diseases like cancer.
- Liquid biopsy solutions for non-invasive cancer detection and monitoring through blood samples.
- Hereditary cancer testing to identify genetic predispositions to various cancers, enhancing personalized treatment planning.
- Genomic data storage and security services that ensure the integrity and confidentiality of sensitive genetic information.
- Collaborative data-sharing platform that enables researchers and clinicians to exchange genomic and phenotypic data, advancing personalized medicine.
- AI-driven analytics for clinical trials, optimizing patient selection and enhancing drug development processes.
equipe executiva do Sophia Genetics SA
- Jurgi CamblongCo-Founder & Executive Chairman
- Ross Jordan MukenCEO & Director
- George A. CardozaExecutive VP & CFO
- Abhimanyu VermaEVP & Chief Technology Officer
- Zhenyu XuExecutive VP & Chief Scientific Officer
- Kellen SangerHead of Strategy and Investor Relations
- Daan van WellExecutive VP and Chief Legal & Compliance Officer
- Kevin PuylaertSVP & Chief Sales Officer
- Manuela Da Silva ValenteExecutive VP & Chief People Officer
- Philippe MenuExecutive VP, Chief Medical Officer & Chief Product Officer
Últimas notícias sobre a Sophia Genetics SA
Principais indicadores financeiros
Resultados divulgados pela Sophia Genetics SA, em USD.
- Cap. de mercado
- 670 mi
- Receita (TTM)
- 86,2 mi
- P/L
- —
- LPA (diluído, TTM)
- -1.2
- Dividend yield
- —
- Margem de lucro
- -93.9%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 77,3 mi | -70,9 mi | -79 mi | |
| 65,2 mi | -66,6 mi | -62,5 mi | |
| 62,4 mi | -74,8 mi | -79 mi | |
| 47,6 mi | -87,8 mi | -87,4 mi |